{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-157382","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2025-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.794613+00:00","generated_at":"2026-05-18T08:43:14.522869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"KalVista FY2025: FDA approved EKTERLY; cash $220.6M; R&D down, G&A up","bullets":["FDA approved EKTERLY (sebetralstat) on July 7, 2025 as first oral on-demand HAE treatment; U.S. launch underway.","Cash and marketable securities $220.6M at April 30, 2025, providing runway into 2027.","R&D expenses $71.7M (down from $86.2M); G&A expenses $116.3M (up from $54.3M) driven by pre-commercial costs.","Entered licensing agreements for sebetralstat in Japan (Kaken, $11M upfront) and Canada (Pendopharm).","Six global regulatory submissions under review; new clinical data presented at EAACI, C1-INH, and EAC."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-157382","json":"https://secwatch.observer/filing/0001193125-25-157382.json","markdown":"https://secwatch.observer/filing/0001193125-25-157382.md","text":"https://secwatch.observer/filing/0001193125-25-157382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/0001193125-25-157382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000119312525157382/d83017d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T08:43:14.522869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}